Press Releases

PARSIPPANY, N.J.--(BUSINESS WIRE)-- AdvanSix (NYSE:ASIX) today announced its financial results for the third quarter ending September 30, 2018. The Company generated strong cash flow while managing through a significant planned plant turnaround and lower production output. Third Quarter 2018 Highlights Sales u

ARLINGTON, Va.--(BUSINESS WIRE)-- The AES Corporation (NYSE: AES) today announced that Executive Vice President and Chief Financial Officer,

DUBLIN--(BUSINESS WIRE)-- The "Biopharmaceuticals Manufacturing Consumables Testing Market Analysis Report By Service (Compendial Testing, Laboratory Testing), By Raw Material Type (Excipients, API), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

DUBLIN--(BUSINESS WIRE)-- The "Polyvinyl Butyral (PVB) Market Size, Share & Trends Analysis Report By Application (Films & Sheets, Paints & Coatings, Adhesives), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2024" report has been added to ResearchAndMarkets.com's offering

LONDON--(BUSINESS WIRE)-- Technavio analysts forecast the global swimming pool assisted access lifts marke

MIRAMAR, Fla.--(BUSINESS WIRE)-- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (

PITTSBURGH, Pa. & LOUISVILLE, Ky.--(BUSINESS WIRE)-- PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy®,

BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann, M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors, effective October 31, 2018. Dr. Haumann’s extensive biotech and pharmaceutical leadership experience includes more than 20 years of d

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in Stephens NY Investment Conference in New York City. Presentation takes place on Wednesday, November 7, 2018, at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). Matt Korenberg, CFO, will attend for Ligand. A live webcast of the presentation will be availabl

IRVING, Texas--(BUSINESS WIRE)-- Vizient, the largest member-driven health care performance improvement company in the country and its subsidiary Provista, a leading supply chain partner for non-acute health care delivery organizations, urge CMS to reconsider its approach to the Medicare home infusion therapy benefit to recognize the full array of services needed for home infusion therapy services.

MIRAMAR, Fla.--(BUSINESS WIRE)-- Stemtech Corporation held its first-ever global convention October 17 – 20 in Cancun, Mexico at the award-winning Now Sapphire resort. Independent Business Partners and employees from a dozen countries attended. At the event, Stemtech announced three new, cutting-edge stem cell nutrition products along with the addition of industry icons to its senior global management tea

AUSTIN, Texas--(BUSINESS WIRE)-- HNI Healthcare, Inc. (HNI) closed Thursday on the $25 million purchase of Cleveland-Based Martin Healthcare Group (MHG), a 40-year-old privately held company dedicated to the delivery of inpatient care and staffing solutions to acute and post-acute care hospitals across the Midwest and Florida. By January 2019, the groups will market themselves jointly under the HNI Healthcare m

WHITE PLAINS, N.Y.--(BUSINESS WIRE)-- ITT Inc. (NYSE: ITT) today reported 2018 third-quarter financial results that reflect strong top-line growth and the company’s continued focus on operational execution and strategies to win share in key global end markets. “For the third consecutive quarter, ITT delivered record results and double-digit growth across key metrics including adjusted segment operat

SAN JOSE, Calif.--(BUSINESS WIRE)-- NeoPhotonics Corporation (NYSE: NPTN), a leading designer and manufacturer of optoelectronic solutions for the highest speed communications networks in telecom and data center applications, today announced financial results for its third quarter ended September 30, 2018. “With continued strength in demand in the third quarter, combined with increasing

ROSTOCK, Germany--(BUSINESS WIRE)-- CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced the